NAD+ 1g & Retatrutide : A British Update
The emerging interest in NAD+ supplementation, particularly at a significant dosage of 1000mg , continues to rise within the British medical community. Concurrently, attention is directed toward Retatrutide, a novel GLP-1 receptor agonist being viewed by many as a potential successor to Tirzepati